Work

560TiP A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1082

Authors: S. Crabb, R. Plummer, A. Greystoke, L. Carter, S. Pacey, H. Walter, V.M. Coyle, T. Knurowski, K. Clegg, F. Ashby, N. Pegg, W. West, N. Brooks, A. Hughes, J. de Bono

Institutions: University Hospital Southampton NHS Foundation Trust, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, University of Manchester, The Christie NHS Foundation Trust, Cancer Research UK, Cancer Research UK Cambridge Center, University of Leicester, University Hospitals of Leicester NHS Trust, Queen's University Belfast, CellCentric (United Kingdom), Royal Marsden NHS Foundation Trust

Language: English

Topic: Chromatin Remodeling and Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3203557925

FWCI: 0.314

Cites:

Cited by: 9

Related to: 10